Patient characteristics
| . | Total (N = 171) . |
|---|---|
| Age, median (range) | 59 (18-85) |
| Sex, male, n % | 120 (70) |
| Diagnosis, n % | |
| DLBCL | 133 (78) |
| Transformed follicular lymphoma | 28(16) |
| Primary mediastinal B cell lymphoma | 10 (6) |
| IPI score 3-5, n % | 96 (56) |
| ECOG 0 | 49 (29) |
| >1 Extranodal site | 109 (64) |
| Disease stages III and IV | 140 (82) |
| Prior chemotherapy lines, n [range] | 4 (2-15) |
| Patients refractory to previous treatment line, n (%) | 134 (78) |
| Previous autologous stem cell transplant, n (%) | 45 (26) |
| Toxicity incidence (first 30 d after treatment), n (%) | |
| CRS grade | |
| No CRS | 11 (6) |
| 1 | 79 (46) |
| 2 | 67 (39) |
| 3 | 6 (4) |
| 4 | 8 (5) |
| ICANS grade | |
| No CRS | 62 (36) |
| 1 | 25 (15) |
| 2 | 20 (12) |
| 3 | 36 (21) |
| 4 | 28 (16) |
| . | Total (N = 171) . |
|---|---|
| Age, median (range) | 59 (18-85) |
| Sex, male, n % | 120 (70) |
| Diagnosis, n % | |
| DLBCL | 133 (78) |
| Transformed follicular lymphoma | 28(16) |
| Primary mediastinal B cell lymphoma | 10 (6) |
| IPI score 3-5, n % | 96 (56) |
| ECOG 0 | 49 (29) |
| >1 Extranodal site | 109 (64) |
| Disease stages III and IV | 140 (82) |
| Prior chemotherapy lines, n [range] | 4 (2-15) |
| Patients refractory to previous treatment line, n (%) | 134 (78) |
| Previous autologous stem cell transplant, n (%) | 45 (26) |
| Toxicity incidence (first 30 d after treatment), n (%) | |
| CRS grade | |
| No CRS | 11 (6) |
| 1 | 79 (46) |
| 2 | 67 (39) |
| 3 | 6 (4) |
| 4 | 8 (5) |
| ICANS grade | |
| No CRS | 62 (36) |
| 1 | 25 (15) |
| 2 | 20 (12) |
| 3 | 36 (21) |
| 4 | 28 (16) |